Multi-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: Expert panel recommendations

Göker, Erdem; Altwairgi, Abdullah; Al-Omair, Ameen; Tfayli, Arafat; Black, Elizabeth; Elsayed, Hany; Selek, Uğur; Koegelenberg, C F N

doi:10.1016/j.lungcan.2021.05.025

Cited by 7 publications

(8 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But as reported before, some innovative peri-operative treatments as ERAS protocol and VATS make it possible to minimize health care costs. In order to provide the best care, specific guidelines based on real-life management of patients from specific region [178] are needed.…”

Section: Providing Adequate Cares For Allmentioning

confidence: 99%

The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectives—State of the Art

Montagne

Guisier

Vénissac

et al. 2021

Cancers

View full text Add to dashboard Cite

Non-small cell lung cancers (NSCLC) are different today, due to the increased use of screening programs and of innovative systemic therapies, leading to the diagnosis of earlier and pre-invasive tumors, and of more advanced and controlled metastatic tumors. Surgery for NSCLC remains the cornerstone treatment when it can be performed. The role of surgery and surgeons has also evolved because surgeons not only perform the initial curative lung cancer resection but they also accompany and follow-up patients from pre-operative rehabilitation, to treatment for recurrences. Surgery is personalized, according to cancer characteristics, including cancer extensions, from pre-invasive and local tumors to locally advanced, metastatic disease, or residual disease after medical treatment, anticipating recurrences, and patients’ characteristics. Surgical management is constantly evolving to offer the best oncologic resection adapted to each NSCLC stage. Today, NSCLC can be considered as a chronic disease and surgery is a valuable tool for the diagnosis and treatment of recurrences, and in palliative conditions to relieve dyspnea and improve patients’ comfort.

show abstract

Section: Providing Adequate Cares For Allmentioning

confidence: 99%

The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectives—State of the Art

Montagne

Guisier

Vénissac

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Cancer therapy has stepped into the era of multidisciplinary treatment (MDT), 1 calling for rational and orchestrating combination strategies. 2,3 Traditional therapeutic modalities have unavoidable limitations, such as chemotherapy-associated drug resistance, 4 and eventually, result in tumor survival and poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy

Zhang

Xia

et al. 2023

Bioengineering & Transla Med

View full text Add to dashboard Cite

Melittin, the principal constituent in bee venom, is an attractive candidate for cancer therapy. However, its clinical applications are limited by hemolysis, nonspecific cytotoxicity, and rapid metabolism. Herein, a novel genetically engineered vesicular antibody‐melittin (VAM) drug delivery platform was proposed and validated for targeted cancer combination therapy. VAM generated from the cellular plasma membrane was bio‐synthetically fabricated, with the recombinant protein (hGC33 scFv‐melittin) being harbored and displayed on the cell membrane. The bioactive and targetable nanomelittin conjugated by hGC33 scFv could be released in an MMP14‐responsive manner at tumor sites, which reduced off‐target toxicity, especially the hemolytic activity of melittin. Importantly, VAM could be loaded with small‐molecule drugs or nanoparticles for combination therapy. Nanomelittin formed pores in membranes and disturbed phospholipid bilayers, which allowed the anticancer agents (i.e., chemotherapeutic drug doxorubicin and sonosensitizer purpurin 18 nanoparticles) co‐delivered by VAM to penetrate deeper tumor sites, leading to synergistic therapeutic effects. In particular, the punching effect generated by sonodynamic therapy further improved the immunomodulatory effect of nanomelittin to activate the immune response. Taken together, our findings indicate that clinically translatable VAM‐based strategies represent a universal, promising approach to multimodal synergetic cancer therapy.

show abstract

“…At present, the treatments for lung adenocarcinoma mainly include surgery, radiotherapy and chemotherapy. Although the above treatments can reduce the risk of death in patients with lung adenocarcinoma to a certain extent, the overall survival of patients with lung adenocarcinoma is still very low, and the prognosis is poor because it is difficult to find and easily recurs ( 5 ). Therefore, clarifying the molecular mechanisms of lung adenocarcinoma and identifying novel candidate biomarkers are prerequisites for the early diagnosis of lung adenocarcinoma, which is a key factor for effective treatment.…”

Section: Introductionmentioning

confidence: 99%

Experimental study on the suppressive effect of B3GNT3 on the apoptosis of lung adenocarcinoma cells and its application in early screening for lung adenocarcinoma

Shuai¹,

Peng²,

Lv³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background: Lung adenocarcinoma, as a common histological type in lung cancer, the overall survival is very low, and the prognosis is poor because it is difficult to find and easily recurs. Therefore, this study aimed to explore the role of the secreted protein beta-1,3-N-acetylglucosaminyltransferase 3 (B3GNT3) in the development of lung adenocarcinoma and to evaluate its potential significance for early clinical biomarker screening. Methods:The mRNA expression profiles of patients with lung adenocarcinoma and normal controls were analyzed via The Cancer Genome Atlas (TCGA) database. Serum samples of clinical lung cancer patients and healthy people were obtained, and the differences in B3GNT3 expression in different stages of lung adenocarcinoma and in healthy tissues were compared. Kaplan-Meier (K-M) curves were drawn to clarify the influence of high and low expression of B3GNT3 on the prognosis of patients. Peripheral blood samples from patients with lung adenocarcinoma and healthy people were obtained clinically, and receiver operating characteristic (ROC) curves were drawn to clarify the sensitivity and specificity of B3GNT3 expression for the diagnosis of lung adenocarcinoma. Lung adenocarcinoma cells were cultured in vitro, the expression of B3GNT3 was knocked down by lentivirus infection. The expression of the apoptosis-associated genes was detected by reverse transcription-polymerase chain reaction (RT-PCR). Results:The secreted protein B3GNT3 is significantly differentially expressed in the serum of patients with lung adenocarcinoma versus normal controls. Subgroup analysis according to lung adenocarcinoma clinical stage showed that the higher the clinical stage of lung adenocarcinoma was, the higher the B3GNT3 expression. Enzyme-linked immunosorbent assay (ELISA) revealed that B3GNT3 expression was significantly increased in the serum of patients with lung adenocarcinoma and significantly decreased after surgery. By inhibiting programmed cell death-ligand 1 (PD-L1), the level of apoptosis was significantly increased and the proliferative capacity was significantly inhibited. In contrast, the level of apoptosis was significantly increased and the proliferation ability was significantly inhibited after simultaneous overexpression of B3GNT3 and inhibition of PD-L1.Conclusions: High expression of the secreted protein B3GNT3 in lung adenocarcinoma is closely related to prognosis and can serve as a potential biological marker for the early screening of lung adenocarcinoma.

show abstract

Multi-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: Expert panel recommendations

Cited by 7 publications

References 96 publications

The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectives—State of the Art

The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectives—State of the Art

Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy

Experimental study on the suppressive effect of B3GNT3 on the apoptosis of lung adenocarcinoma cells and its application in early screening for lung adenocarcinoma

Contact Info

Product

Resources

About